Nrf2-driven TERT regulates pentose phosphate pathway in glioblastoma

Cell Death and Disease

Volumn 7, Issue , 2016, Pages

  Ahmad, F ^a   Dixit, D ^a   Sharma, V ^b   Kumar, A ^b   Joshi, S D ^a   Sarkar, C ^b   Sen, E ^a  

^a NATIONAL BRAIN RESEARCH CENTRE   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

COSTUNOLIDE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLYCOGEN; GLYCOGEN SYNTHASE; PENTOSE PHOSPHATE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR NRF2; TRANSKETOLASE; ANTINEOPLASTIC AGENT; NFE2L2 PROTEIN, HUMAN; SESQUITERPENE; TELOMERASE; TERT PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE MUTATION; GENE OVEREXPRESSION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BRAIN NEOPLASMS; CELL AGING; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PENTOSE PHOSPHATE CYCLE; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; CELL AGING; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; GLUCOSEPHOSPHATE DEHYDROGENASE; GLYCOGEN; GLYCOGEN SYNTHASE; HUMANS; MICE; MICE, NUDE; NF-E2-RELATED FACTOR 2; PENTOSE PHOSPHATE PATHWAY; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; SESQUITERPENES; SIGNAL TRANSDUCTION; TELOMERASE; TRANSKETOLASE; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84971349458     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2016.117     Document Type: Article

References (44)

1. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB et al. Extension of life-span by introduction of telomerase into normal human cells. Science (New York, NY) 1998; 279: 349-352.
2. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL et al. Specific association of human telomerase activity with immortal cells and cancer. Science (New York, NY) 1994; 266: 2011-2015.
3. Nakayama J, Tahara H, Tahara E, Saito M, Ito K, Nakamura H et al. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 1998; 18: 65-68.
4. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999; 5: 1164-1170.
5. Zhang X, Mar V, Zhou W, Harrington L, Robinson MO. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev 1999; 13: 2388-2399.
6. Indran IR, Hande MP, Pervaiz S. hTERT overexpression alleviates intracellular ROS production, improves mitochondrial function, and inhibits ROS-mediated apoptosis in cancer cells. Cancer Res 2011; 71: 266-276.
7. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 2006; 10: 241-252.
8. Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V et al. Frequency of TERT promoter mutations in human cancers. Nat Commun 2013; 4: 2185.
9. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr. et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 2013; 110: 6021-6026.
10. Ahmed S, Passos JF, Birket MJ, Beckmann T, Brings S, Peters H et al. Telomerase does not counteract telomere shortening but protects mitochondrial function under oxidative stress. J Cell Sci 2008; 121: 1046-1053.
11. Santos JH, Meyer JN, Van Houten B. Mitochondrial localization of telomerase as a determinant for hydrogen peroxide-induced mitochondrial DNA damage and apoptosis. Hum Mol Genet 2006; 15: 1757-1768.
12. Zhao BX, Zhao Y, Huang Y, Luo LM, Song P, Wang X et al. The efficiency of tumor-specific pH-responsive peptide-modified polymeric micelles containing paclitaxel. Biomaterials 2012; 33: 2508-2520.
13. Sahin E, Colla S, Liesa M, Moslehi J, Muller FL, Guo M et al. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 2011; 470: 359-365.
14. Hu J, Hwang SS, Liesa M, Gan B, Sahin E, Jaskelioff M et al. Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer. Cell 2012; 148: 651-663.
15. Chin L, Artandi SE, Shen Q, Tam A, Lee SL, Gottlieb GJ et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999; 97: 527-538.
16. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R et al. TIGAR, a p53- inducible regulator of glycolysis and apoptosis. Cell 2006; 126: 107-120.
17. Song Y, Li X, Li Y, Li N, Shi X, Ding H et al. Non-esterified fatty acids activate the ROS-p38- p53/Nrf2 signaling pathway to induce bovine hepatocyte apoptosis in vitro. Apoptosis 2014; 19: 984-997.
18. Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 2009; 284: 13291-13295.
19. Singh A, Happel C, Manna SK, Acquaah-Mensah G, Carrerero J, Kumar S et al. Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. J Clin Invest 2013; 123: 2921-2934.
20. Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 2012; 22: 66-79.
21. Shay JW, Wright WE. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis 2005; 26: 867-874.
22. Favaro E, Bensaad K, Chong MG, Tennant DA, Ferguson DJ, Snell C et al. Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells. Cell Metab 2012; 16: 751-764.
23. Dikmen ZG, Gellert GC, Jackson S, Gryaznov S, Tressler R, Dogan P et al. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res 2005; 65: 7866-7873.
24. Choi SH, Im E, Kang HK, Lee JH, Kwak HS, Bae YT et al. Inhibitory effects of costunolide on the telomerase activity in human breast carcinoma cells. Cancer Lett 2005; 227: 153-162.
25. Dixit D, Ghildiyal R, Anto NP, Sen E. Chaetocin-induced ROS-mediated apoptosis involves ATM-YAP1 axis and JNK-dependent inhibition of glucose metabolism. Cell Death Dis 2014; 5: e1212.
26. Wang Z, Zhao X, Gong X. Costunolide induces lung adenocarcinoma cell line A549 cells apoptosis through ROS (reactive oxygen species)-mediated endoplasmic reticulum stress. Cell Biol Int 2016; 40: 289-297.
27. Dixit D, Sharma V, Ghosh S, Koul N, Mishra PK, Sen E. Manumycin inhibits STAT3, telomerase activity, and growth of glioma cells by elevating intracellular reactive oxygen species generation. Free Radic Biol Med 2009; 47: 364-374.
28. Sharma V, Joseph C, Ghosh S, Agarwal A, Mishra MK, Sen E. Kaempferol induces apoptosis in glioblastoma cells through oxidative stress. Mol Cancer Ther 2007; 6: 2544-2553.
29. Shats I, Milyavsky M, Tang X, Stambolsky P, Erez N, Brosh R et al. p53-dependent downregulation of telomerase is mediated by p21waf1. J Biol Chem 2004; 279: 50976-50985.
30. Munoz-Pinedo C, El Mjiyad N, Ricci JE. Cancer metabolism: current perspectives and future directions. Cell Death Dis 2012; 3: e248.
31. Jiang P, Du W, Wang X, Mancuso A, Gao X, Wu M et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol 2011; 13: 310-316.
32. Stanton RC. Glucose-6-phosphate dehydrogenase, NADPH, and cell survival. IUBMB Life 2012; 64: 362-369.
33. Volonte D, Liu Z, Musille PM, Stoppani E, Wakabayashi N, Di YP et al. Inhibition of nuclear factor-erythroid 2-related factor (Nrf2) by caveolin-1 promotes stress-induced premature senescence. Mol Biol Cell 2013; 24: 1852-1862.
34. Manchester J, Skurat AV, Roach P, Hauschka SD, Lawrence JC Jr. Increased glycogen accumulation in transgenic mice overexpressing glycogen synthase in skeletal muscle. Proc Natl Acad Sci USA 1996; 93: 10707-10711.
35. Ros S, Schulze A. Linking glycogen and senescence in cancer cells. Cell Metab 2012; 16: 687-688.
36. Park CK, Lee SH, Kim JY, Kim JE, Kim TM, Lee ST et al. Expression level of hTERT is regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma. Oncotarget 2014; 5: 3399-3407.
37. Kovac S, Angelova PR, Holmstrom KM, Zhang Y, Dinkova-Kostova AT, Abramov AY. Nrf2 regulates ROS production by mitochondria and NADPH oxidase. Biochim Biophys Acta 2015; 1850: 794-801.
38. Jaramillo MC, Zhang DD. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev 2013; 27: 2179-2191.
39. Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA 2008; 105: 13568-13573.
40. Lee WN, Guo P, Lim S, Bassilian S, Lee ST, Boren J et al. Metabolic sensitivity of pancreatic tumour cell apoptosis to glycogen phosphorylase inhibitor treatment. Br J Cancer 2004; 91: 2094-2100.
41. Koh CM, Khattar E, Leow SC, Liu CY, Muller J, Ang WX et al. Telomerase regulates MYCdriven oncogenesis independent of its reverse transcriptase activity. J Clin Invest 2015; 125: 2109-2122.
42. Cheung EC, Athineos D, Lee P, Ridgway RA, Lambie W, Nixon C et al. TIGAR is required for efficient intestinal regeneration and tumorigenesis. Dev Cell 2013; 25: 463-477.
43. Tewari R, Choudhury SR, Ghosh S, Mehta VS, Sen E. Involvement of TNFalpha-induced TLR4-NF-kappaB and TLR4-HIF-1alpha feed-forward loops in the regulation of inflammatory responses in glioma. J Mol Med (Berl) 2012; 90: 67-80.
44. Dixit D, Sharma V, Ghosh S, Mehta VS, Sen E. Inhibition of Casein kinase-2 induces p53- dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFalpha)-induced apoptosis through SIRT1 inhibition. Cell Death Dis 2012; 3: e271.